^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Excerpt:
Kymriah is indicated for the treatment of...Paediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Acute Lymphoblastic Leukemia: Preferred Regimens…Tisagenlecleucel (for B-ALL) (patients <26 y and with refractory disease or ≥2 relapses)